LEHI, Utah, May 29, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will be participating at the upcoming conferences: BIO International Convention taking place June 3-6 in San Diego and at the European Hematology Association (EHA) 2024 Hybrid Congress taking place June 13-16 in Madrid, Spain.
LEHI, Utah, May 14, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the unveiling of a new clinical program evaluating its candidate HT-4253 for the treatment of Alzheimer's disease. David J. Bearss, Ph.D., President, and CEO of Halia Therapeutics, will present the scientific rationale and preclinical data for the groundbreaking clinical program HT-4253 in an oral presentation at the Discovery Europe 2024 Conference, taking place May 22 – 23, in Basel, Switzerland.
LEHI, Utah, April 17, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of Halia Therapeutics, will present at the Asia BIO 2024 Conference on April 24.
LEHI, Utah, Feb. 6, 2024 /PRNewswire/ -- Halia Therapeutics, a pharmaceutical company at the forefront of developing neuroinflammation-targeting drugs, and Canary Speech, a leader in artificial intelligence vocal biomarker technology, today announced a collaboration to revolutionize the way Alzheimer's disease can be monitored and treated.
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th World Gastroenterology, IBD & Hepatology Conference taking place during December 15-17, 2023, in Dubai, United Arab Emirates and virtually.
LEHI, Utah, Dec. 13, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). HT-6184 is a selective and orally bioavailable first-in-class inhibitor of NLRP3/NEK7 inflammasome, a main driver of inflammatory diseases, as well as hematologic and other malignancies.
LEHI, Utah, Nov. 27, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that it will be presenting at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 9 – 12, 2023, in San Diego, California, and virtually.
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that David Bearss, Ph.D., President and Chief Executive Officer of Halia, will be participating in a panel discussion and presenting new data at the 5th Inflammasome Therapeutics Summit taking place on November 28 – 30, in Boston, MA.
Halia Appoints Former Amgen Scientists, Lisa Shamon as Vice President
Halia Continued Support to Utah's Industry Community Recognized by First Place